• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Disclosed is the isolation and cloning of genes encoding glucanohydrolase enzymes and the expression and secretion of exogenous glucanase gene products in host cells. Disclosed also are dental caries preventative preparations and methods for their preparation and use which involve microbial host cells indigenous to the oral cavity transformed to express and secrete glucanase gene products.
    公开号:SU1720493A3
    申请号:SU864027298
    申请日:1986-03-20
    公开日:1992-03-15
    发明作者:Мацусиро Аизо
    申请人:Аизо Мацусиро (JP)；
    IPC主号:
    专利说明:

    The invention relates to biotechnology and pharmacology, and relates to methods for producing preparations for dentistry.
    A method was developed for the preparation of a strain of Streptococcus sanguis expressing an a-1,3-glucan-3-glkanogidrolazu, which concluded that a 3 T EcoRI fragment of Bacillus circulans BC-8/1-Ferm was isolated. bp, clone it into plasmid pYEIOOl, then into vectors pGB301, pMN2, pMNI, pMN3. The resulting plasmids containing the α -1,3-g yucan-3-glucan hydrodrolase gene transform Streptococcus sanguis cells.
    Example 1. A soil sample containing weathered granite mixed with peat and having a pH of approximately 6 contains a minimal medium sterilized with phosphate buffered (pH 7) and containing 0.1 May. % (NtafeSO, 0.005 wt.% Mo., 0.0005 wt.% FeCte 6H20 and 0.03 wt.% Insoluble glucan, obtained from the karyogenic strain of Streptococcus mutans OM Z 176, which is a carbon source, Soil samples are incubated in Wednesday for three days at 28 ° C.
    The bacteria family cultured in this medium is subcultured twelve times and then concentrated. Flat agars are obtained containing 1.2% by weight of agar, to which 0.2% insoluble glucan and minimal medium are added. The plates are grafted with a concentrated culture of bacteria and cultured until the formation of colonies. After several days, during which incubations are carried out at 30 ° C, bacteria expressing glucanase activity and destroying insoluble glucan are identified by forming transparent halos around the colonies.
    The four colonies that make up the most noticeable halo are deposited.
    V |
    you about

    00
    in the Technical Research Institute of the Microbiological Industry, Japan, under the numbers PERM BP-733 and PERM BP-995.
    P r and me p2. To determine the activity of the glucanase enzyme, a suspension of insoluble glucan (Example 1) is crushed by sonication and used as a substrate. The BS-8 culture of Bacillus circulars (hereafter BS-8) is incubated in tripticase soy broth at 30 ° C. The expression of the enzyme glucanase is initiated by the addition of insoluble glucan. Samples of the upper layer containing the enzyme are obtained by centrifugation and 10-fold concentration of the culture medium. Or the top layer is treated with 75% ammonium sulfate in order to carry out the deposition of the enzyme. The amount of enzyme activity that is taken is that which produces 0.1 mM glucose for 16 hours at 37 ° C from an insoluble glucan substrate.
    PRI me R 3. BS-8 bacteria cultures were incubated in 500 ml of soybean trypticase broth containing 0.3% insoluble glucan for three days at 30 ° C. The top layer of the culture, obtained by centrifugation, is treated with a 75% solution of ammonium sulfate, so that the enzyme is transferred to the sediment. The resulting precipitate was dissolved in 50 mM phosphate buffer solution (pH 7.0) and applied to a DE-52 cellulose column. Fractions are collected by elution with 50 mM phosphate buffer solution (pH 7) with increasing NaCI concentration from 0 to 0.5 M. The fraction with activity peak is subjected to chromatography on a Sephadex 1-150 column. As a result of electrophoresis, two bands are detected in the gel, one at 68 kilodalton (kD) “of another 54 kD (molecular masses). A 68 kD protein was identified as a-1,3-glucanase, while a 54 kD protein was identified as having activity a-1, b-glucanzes.
    A protein with a molecular weight of 68 kDa is purified using the procedure described above and applied to glcane, whose chemical bonds of type a-1.6 are previously destroyed as a result of treatment with iodine acid or industrial dextranase having only a- 1.3 chemical bonds. A protein with a molecular weight of 68 kD destroys C-1.3 bonds and gives reducing sugars. An enzyme with a molecular weight of 54 kDa possesses Glucanase activity, characteristic of a-1.6 bond, and is thus a-1,6-glucan-6 "glucanohydrolase.
    Although the chemical bonds of the insoluble glucan belong mainly to the a-1,3 family and that a-1,3-glucanase plays a major role in the enzymatic degradation of the insoluble glucan, it has been found that the combination of a-1,3-glucanase and a -1,6-glucanase gives a synergistic effect in the degradation of insoluble glucans. Therefore, in order to remove the insoluble glucan, it is preferable to clone both genes of both a-1,3-glucanase and a-1,6-glucanase, and linking them in the same plasmid.
    PRI me R 4. Bacteria BS-8 are cultivated in soy broth trypticase and DNA is extracted. DNA is centrifuged in a CSCI-EtBr density gradient. However, the presence of plasmid DNA was not detected. Next, a single band of chromosomal DNA is isolated and purified. The DNAs are dialyzed and digested with the endonuclease EcoRI.
    At the same time, the culture of E. coli HB 101, containing the commercially produced plasmid PYEI001, is cultured in 300 ml of L-broth (containing 10 g of peptone, 5 g of yeast extract, 1 g of glucose, 5 g of NaCI and 1000 ml of H20) with a pH of 7, 2 Plasmid DNA PYEI001 is then extracted and digested with EcoRI.
    One mg of the DNA fragment EcoRI BS-8 and one mg of the plasmid PYEI001 DNA are ligated with T4 ligase, the DNA of the recombinant plasmid is transformed into the strain HB 101 E. coll. K12.
    PRI me R 5. It is known that the insertion of a DNA fragment into the EcoRI site of the chloramphenicol resistance gene (Cmr) of the plasmid PYEI001 makes bacteria susceptible to chloramphenicol.
    Among the colonies of the E.coli culture, which were transformed with recombinant plasmid PYEI001, clones with Cm sensitivity were selected and further identified for the presence of the a-1.3 glucanase gene with the correct orientation:
    Since HB 101 bacteria requires threonine, leucine and proline for growth, Cm-sensitive (Cm1) E. coli lines are cultivated on synthetic minimal medium containing a small amount of casamino acids and 0.2% sonicated insoluble glucan as the sole carbon source. . Despite the fact that not a single halo has been obtained and it is assumed that the transformed bacteria
    are able to secrete a-1,3-glucanase, some of the colonies give growth, this indicates that they express the product of the a-1,3-glucanase gene and, thus, acquire the ability to destroy and assimilate insoluble glucan as a carbon source.
    Those transformed cultures that grow on minimal medium are cultured and their DNA is extracted, digested with the EcoRI endonuclease, and a DNA fragment of 3.0 kb is obtained using gel electrophoresis.
    Cultures of E. coli CB 101, bacteria CB 101 transformed with plasmid PYEI001 and bacteria CB 101 transformed with plasmid PYEI001, including insertion of a DNA fragment of 3.0 kb, are cultured. The top layer obtained by centrifuging lysed cells from three types of cultures was analyzed for glucanase activity in accordance with the procedure of Example 2. As a result, it was found that only bacteria transformed with the plasmid PYEI001 containing the fragment in 3.U kb. exhibit glucanase activity. Thus, this proves the correct insertion of the a-1,3-glucanase gene of the BS-8 bacterium into the plasmid PYEIOOIE.coll. In addition, only HB 101 cells transformed with the plasmid PYEI001, including an insert of 3.0 kb, able to survive in kanamino acids and insoluble glucan.
    Example The strain (CTC NO.) Of Streptococcus sanguis Challis bacteria, which is contained in the oral flora, is transformed with a gene coding for the expression of a-1,3-glucanase. Among the various bacteria, S.sanguis and Streptococcus salivarius are the most harmless, in particular the Streptococcus sanguis Challis strain (no. CTC7868) is a good material for geneticists, whose transformation they are relatively well aware of. Plasmid pGB301 is used as a transformation vector.
    The plasmid pGB301 DNA, which is contained in the cytoplasm of S.sanguis Challis, contains two drug resistance markers, Emr (erythromycin) and Stg (chloramphenicol) with a single Bst E II site within the Cmr gene. The plasmid pGB301 DNA is hydrolyzed with the Bst E II cross section enzyme, and the ends are blunt using DNA polymerase I.
    At the same time, the plasmid PYEI001 containing the 3.0t.p. fragment, encoding the expression of the gene # -1,3-g of yucanase, is treated with the EcoRI endonuclease and the ends of the fragment to 3.0 kb. transform into blunt DNA polymerase I. The DNA fragment of the plasmid pGB301 and the DNA fragment of the a-1,3-5 glucanase gene are ligated using 100 units. T4 ligase for plasmid recovery.
    The strain S.sanguis Challis is transformed with a ligase mixture, cultured on flattened agars of the brain nucleus (B.H.I) containing erythromycin (50 mg / ml). Each of these colonies was transferred onto B.H.I. flat agar containing chloramphenicol (10 mg / ml) so that
    5 to establish the presence of Cms (sensitive to chloramphenicol) colonies.
    Even for those strains of S. sanguis Challls that are sensitive to chloramphenicol, phenotypic expression
    0 of the inserted α-1,3-glukanzza gene was found in only one third of the transformed colonies. This is because a fragment of the gene can be inserted with two different orientations. Expression
    5 of the gene product is analyzed by means of the transfer of colonies of St8 bacteria to flat agars from V.H.1. Containing insoluble glucan. Due to the fact that S.sanguis is a gram-positive bacterium, it is possible
    0 it will secrete any a-1,3-glucanase it synthesizes. The expression and secretion of glucanase is determined by the presence of a halo on agar plates. Thus, the a-1, 3-glucan5 gene is correctly introduced into the cells of S.sanguis bacteria, which is generally present in the oral cavity, and the phenotypic expression of this gene can be carried out in this host.
    0 Example. Plasmid pGB301 has two stable markers of resistance to erythromycin and chloramphenicol and has several limitations for its effective use. The number of copies of the plasmid
    5 pGB301 in S.sanguis cell is approximately equal to ten. As a result of a small number of copies, it is very inefficient to cultivate small amounts of S.sanguis containing the plasmid pGB301, and to perform simple plasmid size analyzes or grow large quantities of transformed S. sanguis and obtain plasmid DNA.
    To eliminate these limitations, plasmids pGB301 and pIC9 are dissected through the Sma I sites, which makes it possible to obtain linear molecules with blunt ends on both sides. The DNA fragments are ligated and transformed into E. coli IM 103 strain (PI).
    Colonies that are identified as containing a marker (ac and having plasmids of 12 kb in size are selected, and the plasmid is designated as pM no. 1.
    This plasmid is used as a transfer vector for transformation of the S.sanguls culture in accordance with the description given above, put the transformed culture into ampicillin resistance, as well as chloramphenicol and erythromycin resistance.
    The CE-1,3-glucanase gene must be inserted in the right direction relative to the synthetic promoter that precedes the B to A. region. In this configuration, one can expect vigorous expression and obtain a large amount of synthesized α-1,3-glucanase. Since none of these strains was isolated, the signal peptide of the a-1,3-glucanase gene product BS-8 was not cut off by the E.cotf signal peptidase. In addition, if the production of a-1,3-glucanase when excessively regulated by a powerful synthetic promoter is excessive, the bacterium that accumulates a-1,3-glucanase in the cell dies.
    In cases where the cc-1,3-glucanase gene is inserted in the opposite direction, i.e. from A to B, transcription of the a-1,3-glucanase gene of the BS-8 bacterium takes place under the action of a regular promoter. Such transcription is reduced to a very low level due to the strong competing effect of transcription, which regulates with the synthetic promoter. This fact is also confirmed by an experiment in which the α-1,3-glucanase gene is inserted under non-inductive conditions downward from strong promoters such as the promoter tryptophan (Ptrp) or the lactose promoter (Plac) of the E.coll culture. In these cases, products of genes inserted in both the correct and reverse directions were obtained. The genes inserted in the right direction give significantly more vigorous production of a-1,3-glucanase.
    Thus, in order to efficiently produce glucanase, part of the secretion signal peptide must be modified so that the signal peptide can be easily removed from the glucanase enzyme, and the α-1,3-glucanase gene must be inserted in the correct position.
    go down from a strong promoter.
    Example (-Lactamase) - a product of the ampicillin resistance gene (Am1), is subjected to efficient expression in E.coll culture, as well as in cultures

    5 0 5
    0 5 9 5
    0
    five
    S.sanguls.pMN1 is hydrolyzed with the BstEl endonuclease, and the resulting ends are blunt. At the same time, the plasmid PYEI001 is hydrolyzed with the EcoRI endonuclease in order to remove a fragment of the glucanase gene in 3.0t.p.o., and then the resulting ends are blunt. This fragment is then ligated with the pMN1 fragment.
    The gene fragment containing the promoter and signal secretion peptide of the β-lactamase is cut off from the plasmid pGH54 and inserted into the Nurl site inside the DNA encoding the a-1,3-glucanase gene on pMM1 into which this gene was inserted.
    The Nurl site has been found to be in the region of the glucanase gene encoding the amino terminus of the enzyme polypeptide. To complete this construct, a synthetic linker that serves to combine the DNA encoding the signal peptide / J-lactamase on the pGH54 fragment with the residue of the glucanase gene (from 3 to the Nurl site) is used, and DNA (from 5 to the Nurl site) encoding the amino acid the end of this enzyme.
    PRI me R 9. A fragment of the gene containing the promoter and signal secretion peptide for streptokinase is cloned into Streptococcus equlclmllls and its main sequence is determined. This genetic sequence encodes the secretion of streptokinase by S. equiclmllis cells, as well as E. coli. Plasmid pMN3 is obtained by synthesizing a DNA sequence corresponding to the promoter and signal peptide of this enzyme glucanase gene from region 5 to the Nurl site, and ligating the synthesized DNA sequence to the Nurl site in the plasmid pHN1, which is pretreated to include the gene coding protein a-1,3-glucanase.
    Cultures of the IM103 strain E.coll and S.sanguis can be transformed in accordance with the procedures described in the formula using plasmids pMN2 and pMN3. Transformed cells will contain a significant amount of α -1.3; glucases and S.sanguls cells will secrete the enzyme.
    Thus, the phenotype of the expression of the α-1,3-glucanase gene in the S.sanguls culture is established. Inserting the glucanase gene in the right direction relative to the promoter and replacing the signal peptide with a peptide that functions in S.sanguis cells are important properties for the expression and secretion of large quantities of α-1,3-glucanase.
    Non-S.sanguis bacteria that are natural to the oral cavity and can be used in accordance with the invention include other Streptococcus species, for example Streptococcus sallvarlus. A gene can be introduced into these bacteria using procedures similar to those described for the transformation of S.sanguis.
    Preparations to prevent dental caries contain a bacterium native to the oral cavity. The a-1,3-glucanase gene and the a-1, 6-glucanase gene, or both, produce enzymes that destroy insoluble glucan produced by cariogenic bacteria, which causes tooth decay. Accordingly, the subject matter of the invention can be mounted on the teeth by any means so that the expression and secretion of enzymes
    glucanase by continuous action destroyed insoluble glucan synthesized by cariogenic bacteria in the oral cavity.
    权利要求:
    Claims (1)
    [1]
    The invention of the method for producing a strain of Streptococcus sanguls capable of secreting " -1.3-glucan-3-glucan hydrolase, which consists in the isolation of E. coRI Bacillus clrculans BC-8 / PERM BP-733 DNA fragment of 3.0 kV , cloning of the extracted DNA fragment into plasmid PYEI001, constructing a vector containing the a-1,3-glucan-3-glucan hydrolase gene, subcloning the DNA fragment cloned into PYEI001 into the pGB3C1 or pMN1 vector, or pMN2, or pMN1, followed by transforming the resulting recombinant DNA of Streptococcus anguis bacteria.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1720493A3|1992-03-15|Method for preparation of strain streptococcus sanguis, which is able to produce @@@-1,3-glucan-3-glucanohydrolase
    DE69833652T2|2006-09-21|SYSTEM FOR EXPRESSING A HYPERTHERMOSTABILITY PROTEASE
    HU205386B|1992-04-28|Process for expressing cloned lysostaphin gene and for producing dna fragment containing the gene, expression vector and transformed host cell
    EP0459385B1|1996-01-17|Maltopentaose producing amylases
    JPH07278195A|1995-10-24|Recombinant g-csf
    DE3390105C2|1993-01-07|
    EP0468411B1|1995-11-29|A mutant of bacterium Clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
    JP3433807B2|2003-08-04|Method for producing a useful substance using Bacillus brevis incorporating an expression vector carrying a novel amino acid sequence and a DNA encoding the amino acid sequence
    JPH10500565A|1998-01-20|Expression plasmid controlled by osmB promoter
    US5290916A|1994-03-01|Purified glucanase enzymes
    EP0400569B1|1995-04-19|Method for preparing a vaccine from Streptococcus mutans for dental caries and vaccinal compositions for dental caries used as nasal drops
    KR100457879B1|2004-11-18|Plasmid originated from Bifidobacterium, recombinant expression vector using the plasmid and transformation method
    EP0524604B1|1998-10-14|Process for the preparations of S-|-2,2-dimethyl-cyclopropane carboxamid by genetically engineered microorganismes
    EP0220714A2|1987-05-06|DNA fragment containing the cyclodextrin-glycosyl-transferase gene, expression vector, microorganisms for expression and preparation process
    EP0469523B1|1995-04-19|Cloning and overexpression of glucose-6-phosphate dehydrogenase of Leuconostoc dextranicus
    DE60034318T2|2008-01-03|A-AGARASE AND METHOD FOR THE PRODUCTION THEREOF
    US20060051336A1|2006-03-09|Bacteriolytic complex, method of its production, and strain for realization of the method
    EP1169461A2|2002-01-09|Production of pancreatic procarboxy-peptidase b, isoforms and muteins thereof, and their use
    JP3089287B2|2000-09-18|Manufacturing method of caries vaccine
    EP1418230A2|2004-05-12|Genetically modified penicillin amidase and methods of producing it
    DE19929485A1|2001-01-11|Lytic enzyme
    JP2688861B2|1997-12-10|Branching enzyme gene, microorganism having the gene, and method for producing branching enzyme using the microorganism
    KR100243526B1|2000-02-01|An aminopeptidase purified from aspergillus flavus and a method removing methionine residue from recombinant
    DE3220333A1|1983-01-27|27-Deamidosecretin and process for preparing it by recombinant DNA technology
    GB2221908A|1990-02-21|Recombinant plasmids and vectors and modified synechocystis cyanobacterium host
    同族专利:
    公开号 | 公开日
    EP0195672A3|1988-07-06|
    AU5493786A|1986-09-25|
    EP0195672B1|1991-10-16|
    DE3681946D1|1991-11-21|
    KR860007377A|1986-10-10|
    AU592328B2|1990-01-11|
    JPS6225A|1987-01-06|
    CA1321962C|1993-09-07|
    EP0195672A2|1986-09-24|
    KR940003689B1|1994-04-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS57165312A|1981-04-03|1982-10-12|Handai Biseibutsubiyou Kenkyukai|Production of oral composition|
    FR2529569B1|1982-07-02|1985-07-05|Pasteur Institut|MICROORGANISMS, ESPECIALLY E. COLI, TRANSFORMED BY A DNA SEQUENCE ORIGINATING IN C. THERMOCELLUM, COMPOSITIONS WITH CELLULOLYTIC ACTIVITY FROM THESE MICROORGANISMS AND PROCESS FOR OBTAINING THEM|JPS63185381A|1987-01-27|1988-07-30|Aizo Matsushiro|Production of dextranase|
    EP0311469A3|1987-09-02|1990-05-30|Plant Genetic Systems N.V.|Transformed lactic acid bacteria|
    US4810733A|1987-10-19|1989-03-07|Toyo Ink Mfg Co., Ltd|Color concentrates|
    JPH02157228A|1988-12-12|1990-06-18|Hitachi Ltd|Microorganism and utilizing thereof|
    JPH0687776B2|1990-02-20|1994-11-09|愛三 松代|Novel transformant and method for producing the same|
    JPH054927A|1991-06-28|1993-01-14|Aizo Matsushiro|Lactic acid-containing composition and production thereof|
    IT1270123B|1994-10-05|1997-04-28|Dompe Spa|PHARMACEUTICAL COMPOSITIONS CONTAINING ENGINEERED MICROORGANISMS AND THEIR USE FOR THERAPY|
    AU720045B2|1996-02-09|2000-05-25|Novozymes A/S|Polypeptides having mutanase activity and nucleic acids encoding same|
    WO1997038669A1|1996-04-16|1997-10-23|Novo Nordisk A/S|Compositions for the removal of dental plaque|
    GB2327345B|1997-07-18|1999-06-23|Finnfeeds Int Ltd|Use of an enzyme for manufacturing an agent for controlling bacterial infection|
    US6080849A|1997-09-10|2000-06-27|Vion Pharmaceuticals, Inc.|Genetically modified tumor-targeted bacteria with reduced virulence|
    AU749695B2|1997-09-10|2002-07-04|Vion Pharmaceuticals, Inc.|Genetically modified tumor-targeted bacteria with reduced virulence|
    US6962696B1|1999-10-04|2005-11-08|Vion Pharmaceuticals Inc.|Compositions and methods for tumor-targeted delivery of effector molecules|
    AU2007204037B2|2006-01-04|2013-01-10|Annica Almstahl|Probiotic oral health promoting product|
    AU2011298235B2|2010-08-31|2016-07-21|Centro Superior De Investigacion En Salud Publica |Anticaries compositions and probiotics/prebiotics|
    US11180535B1|2016-12-07|2021-11-23|David Gordon Bermudes|Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    JP5744385|1985-03-20|
    [返回顶部]